Allowing Companies

 
News Articles for Allowing Companies top ^
Alkermes plc (NASDAQ: ALKS) today announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for four of Alkermes’ pipeline candidates for the treatment of central nervous system (CNS) disorders: aripiprazole lauroxil, ALKS 5461, ALKS 3831 and ALKS 7106.
Sign-up for Alkermes Announces Notices of Allowance for U.S. Patents for Four CNS Pipeline Candidates investment picks
http://media.marketwire.com/attachments/201406/76435_horizon.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1137256&ProfileId=051205&sourceType=1 DEERFIELD, IL --
Sign-up for Horizon Pharma Announces U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO(R) (naproxen / esomeprazole) Delayed Release Tablets investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1135334&ProfileId=051205&sourceType=1 DEERFIELD, IL --
Sign-up for Horizon Pharma Announces the U.S. Patent and Trademark Office Issuance of Additional Notices of Allowance With Claims Covering VIMOVO(R) (Naproxen / Esomeprazole) Delayed Release Tablets investment picks
CRANBURY, N.J. , July 9, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/910,422 (the '422 application). The application includes composition of matter claims on broad families of melanocortin receptor‑1 specific peptides with potential utility for treatment of inflammatory diseases and disorders.
Sign-up for Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides investment picks
- Patent will protect MYOS' intellectual property portfolio for Fortetropin through 2033 – CEDAR KNOLLS, N.J., July 24, 2014 (GLOBE NEWSWIRE) -- MYOS Corporation ("MYOS" or the "Company") (Nasdaq:MYOS) , an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it recently received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO") for U.S. Patent Application Serial No.
Sign-up for MYOS Corporation Receives Notice of Allowance of U.S. Patent Application for Proprietary Manufacturing Methods of Fortetropin investment picks
2014/8/27
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G020599-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/8/26/11G020599/Logo1-1336123291.jpg ATLANTA, GA and WARSAW, POLAND--(Marketwired - August 27, 2014) - Perma-Fix Medical S.A. (WARSAW: PFM) , a subsidiary of Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) , and developer of a reliable, cost effective, non-uranium process to produce technetium-99 (Tc-99m), the most widely used medical isotope in the world, today announced that in mid-August 2014, the US Patent Office issued a notice of allowance to Perma-Fix Environmental Services, Inc. allowing all claims in its recent patent application for preparation of its Microporous Composite Material and its derivatives.
Sign-up for US Patent Office Issues Notice of Allowance to Perma-Fix Allowing All Claims of Patent Application for Preparation of Microporous Composite Material and Its Applications investment picks
2014/6/25
By Christian Berthelsen and Lynn Cook The Obama administration has quietly cleared the way for the first exports of unrefined American oil, allowing energy companies to chip away at the four-decade ban on selling U.S. crude overseas.
Sign-up for UPDATE: U.S. set to allow first shipments of unrefined oil overseas investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1140383&ProfileId=051205&sourceType=1 DEERFIELD, IL --
Sign-up for Horizon Pharma Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAYOS(R) (Prednisone) Delayed-Release Tablets investment picks
Intellectual Property Portfolio Broadened for Its Proprietary Transdermal Delivery System PRINCETON, N.J. , July 17, 2014 /PRNewswire/ -- Agile Therapeutics, Inc., (NASDAQ: AGRX) , a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that the U.S. Patent and Trademark Office issued a Notice of Allowance on July 17, 2014 for additional patent claims covering dosing regimens using the Company's lead product candidate Twirla™ (ethinyl estradiol and levonorgestrel transdermal system (AG200-15)), currently in Phase 3 development.
Sign-up for Agile Therapeutics Announces Allowance of Additional Patent Claims for Skinfusion® investment picks
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a notice of allowance for patent application number 14/254,510 covering methods of treating chronic inflammation by intravenous administration of aqueous modified pectin solutions with molecular weights greater than 25 kilodaltons.
Sign-up for La Jolla Pharmaceutical Company Receives Notice of Allowance for Additional Patent Claims Covering Modified Pectin for the Treatment of Chronic Inflammation investment picks
NCR Corporation (NYSE: NCR), the global leader in consumer transaction technologies, announced today that Globe Telecom , a leading telecommunications provider in the Philippines, chose the NCR Bill Pay solution allowing customers to quickly pay their bills in a store without employee assistance.
Sign-up for NCR Bill Pay Solution Allows Globe Telecom to Improve In-Store Customer Experience and Store Operations investment picks
WORCESTER, Mass., Sept.
Sign-up for World Energy Solutions Supports 25th RGGI CO2 Allowance Auction investment picks
TAMPA, Fla., July 1, 2014 (GLOBE NEWSWIRE) -- Rising costs of employer-provided health insurance and the health insurance marketplace for the Affordable Care Act (ACA), which will not hold open enrollment until November, are affecting many Americans' freedom of choice when it comes to selecting health coverage that is both affordable and allows for customization to their very individual needs.
Sign-up for Health Insurance Innovations Allows Consumers to Have the Freedom to Choose Health Insurance for the Individual Needs of All Americans investment picks
PORTLAND, Ore., July 1, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE) , a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced the notice of allowance of a U.S. Patent for NeuVax™ (nelipepimut-S) covering the use of NeuVax alone or in combination to prevent recurrence of any HER2/neu expressing tumor having a fluorescence in situ hybridization (FISH) rating of less than about 2.0. NeuVax is a peptide immunotherapy for the prevention of cancer recurrence and is Galena's lead development agent in multiple ongoing and planned clinical trials.
Sign-up for Galena Biopharma Receives Notice of Allowance of Broad U.S. Patent for NeuVax(TM) (nelipepimut-S) investment picks
PRINCETON, N.J., July 28, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS) , a biotechnology company developing the next generation of cancer immunotherapies, announced that it has received a notice of allowance from the Japan Patent Office for a patent application related to the Advaxis proprietary Lm -LLO cancer immunotherapy platform technology.
Sign-up for Advaxis Receives Notice of Allowance for Cancer Immunotherapies Patent in Japan investment picks
InVivo Therapeutics Holdings Corp.
Sign-up for InVivo Therapeutics Receives Notice of Allowance on Patent Covering Neuro-Spinal Scaffold and Neuro-Spinal Scaffold Plus Stem Cells investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1127086&ProfileId=051205&sourceType=1 PRINCETON, NJ and REHOVOT, ISRAEL --
Sign-up for Rosetta Genomics Receives Notice of Allowance for U.S. Patent for the Prognosis and Treatment of Prostate Cancer investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Allowing Companies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Allocation Stock Funds  |  Next: Allscripts Healthcare